DeepBio becomes first Korean cancer diagnostic A.I. company to win CES Innovation Award

SEOUL, South Korea, Nov. 20, 2023 ~ DeepBio, a Korean cancer diagnosis A.I. company, has been awarded the CES Innovation Award at the world's largest electronics exhibition, CES 2024. This marks the first time a Korean cancer diagnosis A.I. company has won this award.

The Consumer Technology Association (CTA) announced that DeepBio won the Innovation Award in the Digital Healthcare category for its diagnostic-aid software that helps detect meaningful findings among cancer patients.

DeepBio leverages its expertise in deep learning and cancer pathology to provide state-of-the-art in vitro diagnostic software (IVDs, SaMDs) that analyzes various cancers' cancerous areas and severity to help medical professionals make more informed decisions. DeepDx®-Prostate has a high precision of 99% sensitivity and 97% specificity.

More on
Kim Sun-woo, CEO of DeepBio, said: "We have proven our technical excellence both internally and externally, winning the silver medal at the Edison Awards in the United States and first place in 2019 at the Chameleon Challenge." He added: "We will strive to improve the cancer diagnosis environment and provide cutting-edge cancer diagnosis A.I. solutions to medical professionals through generous investment in technology to overcome the biggest challenge of humanity, cancer."

CES 2024 will be held at Las Vegas Convention Center from January 9th to 12th and DeepBio's award can be searched on CES Innovation Awards website.
Filed Under: Business

Show All News | Report Violation


Latest on